Dose Makes the Cure: Venetoclax in Ph- ALL

In this week's episode, Blood editor Dr. James Griffin interviews Dr. Jianxiang Wang from the National Clinical Research Center for Blood Diseases and the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, and Peking Union Medical College in Tianjin, China, on his latest article published in Blood titled "Venetoclax plus pediatric regimen in adolescents and adults with Ph-negative acute lymphoblastic leukemia." In this prospective phase 2 study, 167 adolescents and adults (aged 14-60 years) with ND Ph− ALL received a course of venetoclax combined with pediatric-inspired chemotherapy, to determine the results of this treatment on MRD negativity.